13 results about "TLR7" patented technology

The present disclosure provides methods of treating or inhibiting cancer, reducing its severity, reducing its risk, or inhibiting its metastasis in an individual with a radiation-activated N-oxide TLR7 / 8 agonist.

Lipidized oxoadenines of formula (I) are TLR7 / 8 receptor ligands useful for modulating immune responses. These compounds may have therapeutic applications in the treatment of cancer, infectious diseases, allergies, or autoimmune disorders (SEE FORMULA).

Lipidated oxoadenines of formula (I) are TLR7 / 8 receptor ligands useful for modulating immune responses. The compounds may have therapeutic application in the treatment of cancer, infectious diseases, allergy, or autoimmune disorders.

The present invention provides a method for activating an N-oxide TLR7 / 8 agonist using radiation and a method for treating or inhibiting cancer, reducing its severity, lowering its risk, or inhibiting metastasis.

Lipidated oxoadenines of formula (I) are TLR7 / 8 receptor ligands useful for modulating immune responses. The compounds may have therapeutic application in the treatment of cancer, infectious diseases, allergy, or autoimmune disorders.

This invention discloses a photoactivated nanoparticle-based drug delivery material for immunoadjuvants, its preparation method, and its applications. The drug delivery material is constructed from photosensitizer monomers, crosslinking monomers, and immunoadjuvant prodrug monomers within a confined space of a nanoemulsion via a copper-free click polymerization reaction to form crosslinked polymer nanoparticles. The nanoparticle size is controllable, and the composition is precisely defined. Under physiological conditions, the drug delivery material exhibits good colloidal stability and high drug loading. Upon near-infrared light irradiation, the generated ROS can cleave the thioketone bonds, causing the nanoparticles to depolymerize and achieving photo-triggered, controllable release of the immunoadjuvant. Under photodynamic action, this drug delivery material efficiently generates reactive oxygen species to induce immunogenic cell death in tumor cells. Simultaneously, the released immunoadjuvant activates the TLR7 / 8 pathway, promotes dendritic cell maturation, and enhances the systemic anti-tumor immune response, thereby inhibiting the growth of tumors in situ and at distant sites, and reducing the risk of metastasis and recurrence.

The application discloses an injection containing a compound as shown in formula (I) or a pharmaceutically acceptable salt thereof, and a preparation method of the injection. The preparation method of the injection is simple, the quality of the injection is stable, the injection is convenient for clinical administration, and the injection meets the requirements of subsequent clinical tests.

A method to enhance an immune response in a mammal, and a composition comprising liposomes, a TLR4 agonist and a TLR7 agonist, are provided.

The present invention provides a pharmaceutical composition comprising solid particles comprising at least one toll-like receptor 4 (TLR4) agonist and micelles comprising at least one toll-like receptor 7 (TLR7) agonistfor use as a medicament or for use in the treatment of cancer, an antibiotic resistance, an inflammatory condition or disease, an autoimmune disease or an infectious disease and at least one amphiphilic micelle-forming agent. Also provided is a method of preparing the pharmaceutical composition and a kit or kit of parts comprising the pharmaceutical composition for use.

The present invention provides a pharmaceutical composition comprising solid particles comprising at least one toll-like receptor 4 (TLR4) agonist and micelles comprising at least one toll-like receptor 7 (TLR7) agonist for use as a medicament or for use in the treatment of cancer, an antibiotic resistance, an inflammatory condition or disease, an autoimmune disease or an infectious disease and at least one amphiphilic micelle-forming agent. Also provided is a method of preparing the pharmaceutical composition and a kit or kit of parts comprising the pharmaceutical composition for use.

The present invention provides anti-LIV1 antibodies and immunomodulatory conjugates thereof comprising a TLR7 / 8 dual agonist payload, and their use in treating cancer.

The present invention provides a pharmaceutical composition comprising solid particles comprising at least one toll-like receptor 4 (TLR4) agonist and micelles comprising at least one toll-like receptor 7 (TLR7) agonist and at least one amphiphilic micelle-forming agent. Also provided is a method of preparing the pharmaceutical composition, a kit or kit of parts and the medical use of the pharmaceutical composition and the kit or kit of parts.

The present invention provides a pharmaceutical composition comprising solid particles comprising at least one toll-like receptor 4 (TLR4) agonist and micelles comprising at least one toll-Iike receptor 7 (TLR7) agonist and at least one amphiphilic micelle-forming agent. Also provided is a method of preparing the pharmaceutical composition, a kit or kit of parts and the medical use of the pharmaceutical composition and the kit or kit of parts.